Literature DB >> 9413946

Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).

M Philpott1, W R Joseph, K E Crosier, B C Baguley, L M Ching.   

Abstract

The investigative anti-tumour agent 5,6-dimethylxanthenonone-4-acetic acid (DMXAA, NSC 640488), developed in this laboratory as an improved analogue of flavone acetic acid (FAA, NSC 347512), is currently in clinical trial. The ability of DMXAA to up-regulate tumour necrosis factor (TNF) mRNA and protein synthesis in cultured human peripheral blood leucocytes (HPBLs) has been investigated and compared with that of flavone acetic acid (FAA) and of bacterial lipopolysaccharide (LPS). Human peripheral blood leucocytes were isolated from buffy coats obtained from a blood transfusion centre and also from blood samples from laboratory volunteers. At a concentration of 400 microg ml(-1) and an incubation time of 2 h, DMXAA up-regulated mRNA synthesis in six of eight individuals tested, as measured by Northern blotting. The degree of up-regulation varied in different individuals from one to nine times that of control levels. In contrast, FAA caused no induction above that of control levels and in some cases suppressed expression relative to controls, extending previous data that DMXAA but not FAA up-regulates TNF mRNA in the human HL-60 tumour cell line. At the same concentration but with longer incubation times (6-12 h), DMXAA induced increases in TNF protein in 11 of 15 samples of HPBLs from buffy coats and also in 11 of 15 samples of HPBLs from volunteers, as measured by cytotoxicity assays with L929 cells. FAA caused no increase in TNF protein, while LPS induced TNF to approximately 20-fold higher levels than did DMXAA. Considerable heterogeneity of response was observed with both sources of HPBLs, and there was little or no correlation between the extent of TNF induction by DMXAA and LPS in individual samples. In vitro analysis of the response of human peripheral blood leucocytes to DMXAA may be a useful test in clinical trials of agents such as DMXAA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9413946      PMCID: PMC2228206          DOI: 10.1038/bjc.1997.601

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  26 in total

1.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

2.  Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex.

Authors:  T Spies; C C Morton; S A Nedospasov; W Fiers; D Pious; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

3.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

4.  Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect.

Authors:  G J Finlay; G P Smith; L M Fray; B C Baguley
Journal:  J Natl Cancer Inst       Date:  1988-04-20       Impact factor: 13.506

5.  Endotoxin-stimulated human monocyte secretion of interleukin 1, tumour necrosis factor alpha, and prostaglandin E2 shows stable interindividual differences.

Authors:  J Mølvig; L Baek; P Christensen; K R Manogue; H Vlassara; P Platz; L S Nielsen; A Svejgaard; J Nerup
Journal:  Scand J Immunol       Date:  1988-06       Impact factor: 3.487

6.  Association between HLA-DR2 and production of tumour necrosis factor alpha and interleukin 1 by mononuclear cells activated by lipopolysaccharide.

Authors:  K Bendtzen; N Morling; A Fomsgaard; M Svenson; B Jakobsen; N Odum; A Svejgaard
Journal:  Scand J Immunol       Date:  1988-11       Impact factor: 3.487

7.  Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice.

Authors:  B C Baguley; S B Calveley; K K Crowe; L M Fray; S A O'Rourke; G P Smith
Journal:  Eur J Cancer Clin Oncol       Date:  1989-02

8.  TNF2, a polymorphism of the tumour necrosis-alpha gene promoter, is a component of the celiac disease major histocompatibility complex haplotype.

Authors:  R McManus; A G Wilson; J Mansfield; D G Weir; G W Duff; D Kelleher
Journal:  Eur J Immunol       Date:  1996-09       Impact factor: 5.532

Review 9.  Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.

Authors:  P J O'Dwyer; D Shoemaker; D S Zaharko; C Grieshaber; J Plowman; T Corbett; F Valeriote; S A King; J Cradock; D F Hoth
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347 512).

Authors:  L M Ching; B C Baguley
Journal:  Eur J Cancer Clin Oncol       Date:  1987-07
View more
  6 in total

Review 1.  Vascular targeting agents.

Authors:  Mary Jo Pilat; Julie McCormick; Patricia Mucci LoRusso
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

2.  Pharmacologic activation of the innate immune system to prevent respiratory viral infections.

Authors:  Guanjun Cheng; Liang-Chuan S Wang; Zvi G Fridlender; Guang-Shing Cheng; Bei Chen; Nilam S Mangalmurti; Vassiliki Saloura; Zaifang Yu; Veena Kapoor; Krystyna Mozdzanowska; Edmund Moon; Jing Sun; James L Kreindler; Noam A Cohen; Andrew J Caton; Jan Erikson; Steven M Albelda
Journal:  Am J Respir Cell Mol Biol       Date:  2010-12-10       Impact factor: 6.914

3.  Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404).

Authors:  Liang-Chuan S Wang; Lotte Thomsen; Rachel Sutherland; Charu B Reddy; Sofian M Tijono; Chun-Jen J Chen; Catherine E Angel; P Rod Dunbar; Lai-Ming Ching
Journal:  Neoplasia       Date:  2009-08       Impact factor: 5.715

4.  Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.

Authors:  Z Cao; W R Joseph; W L Browne; K G Mountjoy; B D Palmer; B C Baguley; L M Ching
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

5.  Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.

Authors:  M B Jameson; P I Thompson; B C Baguley; B D Evans; V J Harvey; D J Porter; M R McCrystal; M Small; K Bellenger; L Gumbrell; G W Halbert; P Kestell
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

6.  Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.

Authors:  C J Lash; A E Li; M Rutland; B C Baguley; L J Zwi; W R Wilson
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.